CareDx, Inc

• 10-QQ3 FY2026Positive

  Filed Oct 29

  Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

  • Revenue$139.4MYoY +39.3%
  • Net income$19.3Mvs $1.7M year ago

• 8-KPositiveEarningsGuidance raised

  Filed Oct 29

  Testing Services growth, including NavDx oncology, fuels higher FY2026 revenue guidance of $520M–$530M.

• 10-QQ2 FY2026Positive

  Filed Jul 30

  Naveris adds oncology testing as lab products exit to Eurobio; the sale gain accounts for nearly all operating profit.

  • Revenue$131.9MYoY +52.2%
  • Net income$110.6Mvs −$8.6M year ago

• 8-KPositiveEarningsGuidance raised

  Filed Jul 30

  Transplant testing adoption and favorable reimbursement drive higher FY2026 revenue guidance of $490M–$500M.

• 8-KPositiveDeal completed

  Filed Jul 7

  Sold Lab Products to Eurobio for $171.7M and acquired Naveris for $161.8M upfront, adding NavDx specialty oncology testing.

• 8-KExecutive payShareholder vote

  Filed Jun 15

  Stockholders approved adding 1.6M shares to the 2024 Equity Incentive Plan reserve.

• 10-QQ1 FY2026Mixed

  Filed Apr 28

  Collections on older tests, not just AlloSure and AlloMap volume growth, drove the return to profit.

  • Revenue$117.7MYoY +39.0%
  • Net income$2.8Mvs −$10.4M year ago

• 8-KPositiveEarningsGuidance raised

  Filed Apr 28

  Naveris deal would expand testing into specialty oncology for $160M at closing plus up to $100M in revenue milestones.

• 8-KPositiveEarningsGuidance deferred to the call

  Filed Apr 16

  Agrees to sell Lab Products to Eurobio Scientific for $170M cash to sharpen focus on Testing Services and Patient and Digital Solutions.

• 10-KFY2025Mixed

  Filed Feb 25

  Pharmacy and Ottr expansion drive growth beyond testing, while reimbursement and collection adjustments limit revenue per test.

  • Revenue$379.8MYoY +13.8%
  • Net income−$21.4Mvs $52.5M year ago

• 8-KEarningsNew guidance

  Filed Feb 24

  Testing and patient and digital solutions drove growth; FY2026 revenue guidance of $420M–$444M includes a six-month Medicare LCD impact of ≈$7.5M.

• 8-KPositiveEarnings

  Filed Jan 12

  Higher transplant testing volume and patient & digital solutions growth drove record preliminary Q4 revenue of ≈$108M, +25% Y/Y.

No filings match these filters. Show all 8-K events

Coverage: 10-K, 10-Q and 8-K filings filed since Jan 1, 2026.

Request longer coverage

Company data: Wikidata Q106238469